Paysign将2024财年总收入预测从5450万美元-5670万美元上调至5650万美元-5850万美元（预计5681.8万美元）

Full-year gross profit margins are expected to be between 54.0% and 55.0% versus initial guidance of 52.0% to 54.0% reflecting increased revenue contribution from pharma patient affordability business. 

"Taking all of the factors above into consideration, we expect net income to be in the range of $2.0 million to $3.0 million, or $0.04 to $0.06 per diluted share, and adjusted EBITDA to be in the range of $9.0 million to $10.0 million (15.0% to 17.0% of total revenues), or $0.16 to $0.18 per diluted share."